Biological treatment options for severe asthma in Poland

Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable si...

Full description

Saved in:
Bibliographic Details
Published in:Journal of education, health and sport health and sport, 2024-05, Vol.70, p.51135
Main Authors: Superson, Maciej, Wilk-Trytko, Klaudia, Szmyt, Katarzyna, Samojedny, Sylwia, Szymańska, Katarzyna, Walczak, Kamil, Krasnoborska, Julia, Zarębska, Julia
Format: Article
Language:English
Subjects:
asthma
asthma treatments
biologics
monoclonal antibodies
severe asthma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intruduction and purpose: Patients with severe asthma account for approximately 3% to 10% of all asthma patients. They have higher hospital utilization rates and treatment costs than patients with non-severe asthma. Previously, treatment options for these patients were limited due to unacceptable side effects. However, the advent of biologic therapies has provided promising targeted therapy for these patients. State of knowledge: Biologic therapies target inflammatory modulators that play a key role in the pathogenesis of asthma, particularly in patients with high T2 cells. These therapies have shown promising results in reducing asthma symptoms, improving lung function, decreasing the use of oral corticosteroids, and enhancing patients' quality of life. Conclusions: This article reviews the mechanism of action, efficacy, and indications of currently approved biologic drugs available in Poland, as well as potential therapeutic targets for the future.
ISSN:2391-8306
2391-8306
DOI:10.12775/JEHS.2024.70.51135